S4 + SR-9009 + Cardarine Capsules

S4 + SR-9009 + Cardarine Blend (Capsule Form) – Product Details

• S4 Andarine + Stenabolic + Cardarine Combined Formula capsules contain:
• 30mg S4 Andarine
• 10mg SR-9009
• 10mg Cardarine

Our combination of S4 Andarine, SR 9009, and Cardarine are research chemicals designed to investigate potential applications for promoting lean tissue preservation and metabolic modulation. S4 Andarine is a selective androgen receptor modulator (SARM) that may be studied for its potential in mitigating muscle atrophy and facilitating anabolic signaling pathways.

SR 9009 is a PPARδ agonist hypothesized to enhance lipid oxidation rates and may also contribute to improvements in aerobic capacity. Cardarine, another PPARδ agonist, is being examined for its potential to regulate fatty acid metabolism and augment exercise tolerance in preclinical models. Together, these compounds are under investigation for their collective role in supporting anabolic homeostasis and reductions in adipose tissue. If validated through further research, this combination may have translational relevance for physically active populations in controlled settings.

Note: Researchers interested in further studies may explore similar capsule formulations available in our SARMs Capsules Collection. Additionally, for those investigating the effects of S23, consider reviewing our S-23 Capsules for comparative research.

Disclaimer: Please note that this information is for educational and research purposes only and does not constitute medical advice.

S4 Andarine – Product Information

Andarine S4 belongs to a class of compounds called selective androgen receptor modulators (SARMs), compounds that have the potential to bind to androgen receptors. Androgen receptors are the primary site of action for endogenous androgenic steroids.

Due to its potential role as a biochemical precursor to endogenous androgens, it was initially investigated in research models for addressing reduced bone mineral density and skeletal muscle atrophy.

• CAS Number is stated as 401900-40-1
• Molar Mass is 441.363 g·mol−1
• The chemical formula is C19H18F3N3O6.
• IUPAC Name is (2S)-3-(4-acetamido-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide
• Also known by Synonyms as Acetamidoxolutamide, Androxolutamide, GTx-007.

SR 9009 – Product Information

SR9009, also known as Stenabolic, is an agonist of the Rev-ErbA protein. It has demonstrated the potential to enhance aerobic capacity, promote lipid metabolism, support cardiovascular function, and reduce overall body mass, systemic inflammation, and serum lipid concentrations in murine models.

It was initially researched by Professor Thomas Burris of the Scripps Research Institute for its ability to increase mitochondrial biogenesis in skeletal muscle tissue.

• CAS Number is stated as 1379686-30-2
• Molar Mass is 437.94026 g·mol−1
• It has a Chemical Formula of C20H24ClN3O4S.
• IUPAC Name is ethyl-3-(((4-chlorobenzyl)((5-nitrothiophen-2-yl)methyl)amino)methyl)pyrrolidine-1-carboxylate

Cardarine GW 501516 – Product Information

Cardarine, or GW-501516, is a PPAR agonist. Controlled investigations in research models have indicated that Cardarine may exert favorable effects on various metabolic dysfunctions, including cellular redox imbalance, lipid profile irregularities, excess adiposity, and impaired glucose homeostasis.

Preclinical studies in animal models have demonstrated that Cardarine may improve endurance capacity, stimulate mitochondrial lipid utilization, and elevate high-density lipoprotein (HDL) concentrations. GW-501516 has also shown potential to reduce low-density lipoprotein (LDL) levels, circulating triglyceride concentrations under fasting conditions, and baseline insulin levels in intact murine subjects.

• CAS Number is stated as 317318-70-0
• Molar Mass is 453.49 g·mol−1
• It has a Chemical Formula of C21H18F3NO3S2.
• IUPAC Name is {4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]-2-methylphenoxy}acetic acid
• It is known by synonyms as GW-501, 516, GW1516, GSK-516, Cardarine

How Do S4 + SR 9009 + Cardarine Capsules Work?

S4 Andarine is a selective androgen receptor modulator (SARM) that is believed to function through high-affinity binding to androgen receptors in skeletal muscle and osseous tissue, which may facilitate skeletal muscle hypertrophy and improve muscular force output while concurrently modulating adipose tissue distribution. It is also hypothesized to exert beneficial effects on bone mineral density.

SR9009, on the other hand, is a synthetic molecule that is believed to work by activating a protein called Rev-ErbA, which may potentially contribute to enhanced aerobic capacity, increased cellular energy availability, and elevated basal metabolic rate. This is achieved by promoting mitochondrial biogenesis in muscle cells, which leads to an upregulation of adenosine triphosphate (ATP) synthesis and mitigation of oxidative stress.

Cardarine is a peroxisome proliferator-activated receptor (PPAR) agonist that is believed to function by potentially increasing lipid oxidation for energy production. It has been studied for its role in improving exercise tolerance in experimental models, supporting sustained energy output under caloric restriction. Additionally, Cardarine has demonstrated potential to modulate lipid profiles, which may indicate a reduced risk of cardiovascular-related markers in research settings.

Safety and Side Effects

The safety of administering SR9009, S4 Andarine, and Cardarine has not been fully established, and these compounds are not approved for use in clinical settings by regulatory agencies such as the FDA. Some observed outcomes in preclinical models include alterations in hepatic biomarkers, endocrine disruption, cardiovascular irregularities, and neurocognitive effects.

In addition, prolonged exposure to these compounds in research settings may be associated with elevated risk markers for neoplastic transformations. It is important to note that unsanctioned use outside controlled experimental protocols may significantly elevate the likelihood of adverse biological responses.